You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

CLINICAL TRIALS PROFILE FOR SERTRALINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SERTRALINE HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000321 ↗ Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed Friends Research Institute, Inc. Phase 4 1996-10-01 The purpose of this study is to evaluate the efficacy of desipramine, sertraline, and placebo on methamphetamine dependent gay men with AIDS.
NCT00000321 ↗ Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed National Institute on Drug Abuse (NIDA) Phase 4 1996-10-01 The purpose of this study is to evaluate the efficacy of desipramine, sertraline, and placebo on methamphetamine dependent gay men with AIDS.
NCT00000378 ↗ Antidepressant Treatment of Melancholia in Late Life Completed National Institute of Mental Health (NIMH) Phase 4 1997-07-01 The purpose of this study is to compare the safety and effectiveness of a select serotonin re-uptake inhibitor (SSRI, sertraline) and a tricyclic antidepressant (TCA, nortriptyline) in outpatients over the age of 60 who have major depression. SSRIs are effective in the treatment of major depression. However, there is also evidence that SSRIs may be significantly less effective than TCAs for patients with late-life major depression with melancholia. Since SSRIs seem to be easier to take than TCAs and are more widely prescribed, it is important to determine which of these types of antidepressants works best to treat these patients. Patients will be assigned randomly to receive either sertraline (a SSRI) or nortriptyline (a TCA) for 12 weeks. Patients will be monitored for symptoms, side effects, and quality of life. If a patient responds to treatment, he/she will participate in a 6-month continuation phase in which he/she will continue to receive the same medication. An individual may be eligible for this study if he/she: Has unipolar major depression (with some exceptions) and is over 60 years old.
NCT00000378 ↗ Antidepressant Treatment of Melancholia in Late Life Completed New York State Psychiatric Institute Phase 4 1997-07-01 The purpose of this study is to compare the safety and effectiveness of a select serotonin re-uptake inhibitor (SSRI, sertraline) and a tricyclic antidepressant (TCA, nortriptyline) in outpatients over the age of 60 who have major depression. SSRIs are effective in the treatment of major depression. However, there is also evidence that SSRIs may be significantly less effective than TCAs for patients with late-life major depression with melancholia. Since SSRIs seem to be easier to take than TCAs and are more widely prescribed, it is important to determine which of these types of antidepressants works best to treat these patients. Patients will be assigned randomly to receive either sertraline (a SSRI) or nortriptyline (a TCA) for 12 weeks. Patients will be monitored for symptoms, side effects, and quality of life. If a patient responds to treatment, he/she will participate in a 6-month continuation phase in which he/she will continue to receive the same medication. An individual may be eligible for this study if he/she: Has unipolar major depression (with some exceptions) and is over 60 years old.
NCT00000384 ↗ Treatment of Obsessive-Compulsive Disorder (OCD) in Children Completed National Institute of Mental Health (NIMH) Phase 3 1997-05-01 The purpose of this study is to compare 3 treatments for children with OCD: medication (sertraline, SER) alone vs OCD-specific therapy (Cognitive Behavior Therapy, CBT) vs medication plus therapy. Some patients will receive an inactive placebo (PBO) instead of medication and/or Educational Support (ES, non-psychological treatment) instead of therapy. One in 200 children suffer from OCD, but few receive appropriate treatment. Both CBT and medication seem to be effective, but their effectiveness, alone and in combination, has not been evaluated. There are 2 phases to this trial. In Phase I the child will receive 1 of the following 6 treatments for 12 weeks: 1) SER alone; 2) pill PBO alone; 3) CBT alone; 4) SER plus CBT; 5) SER plus ES; 6) pill PBO plus ES. If the child responds to treatment, he/she will go on to Phase II in which the treatment will be slowly reduced, then stopped (discontinued), over time to test the treatment's durability. The child will be evaluated at Weeks 1, 4, 8, 12 (Phase I treatment), and Weeks 16, 20, 24, and 28 (Phase II discontinuation) to see how effective and durable the treatment is in treating your child's OCD. A child may be eligible for this study if he/she: Has obsessive-compulsive disorder (OCD) and is 8 - 16 years old.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SERTRALINE HYDROCHLORIDE

Condition Name

Condition Name for SERTRALINE HYDROCHLORIDE
Intervention Trials
Depression 77
Major Depressive Disorder 39
Healthy 17
Post-Traumatic Stress Disorder 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SERTRALINE HYDROCHLORIDE
Intervention Trials
Depression 159
Depressive Disorder 134
Depressive Disorder, Major 74
Disease 70
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SERTRALINE HYDROCHLORIDE

Trials by Country

Trials by Country for SERTRALINE HYDROCHLORIDE
Location Trials
United States 523
Canada 45
Japan 20
Brazil 17
China 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SERTRALINE HYDROCHLORIDE
Location Trials
New York 46
California 37
Pennsylvania 33
Texas 31
Massachusetts 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SERTRALINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for SERTRALINE HYDROCHLORIDE
Clinical Trial Phase Trials
PHASE4 2
PHASE3 3
PHASE2 2
[disabled in preview] 162
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SERTRALINE HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 218
Terminated 36
Unknown status 26
[disabled in preview] 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SERTRALINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for SERTRALINE HYDROCHLORIDE
Sponsor Trials
National Institute of Mental Health (NIMH) 53
Pfizer 29
Duke University 13
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SERTRALINE HYDROCHLORIDE
Sponsor Trials
Other 450
Industry 113
NIH 91
[disabled in preview] 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sertraline Hydrochloride: Clinical Trials, Market Analysis and Projections

Last updated: February 20, 2026

What is the current status of clinical trials for Sertraline Hydrochloride?

Sertraline Hydrochloride, a selective serotonin reuptake inhibitor (SSRI), is primarily marketed for depression, anxiety disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). Its initial approval by the U.S. Food and Drug Administration (FDA) occurred in 1991. Since then, no significant Phase III or IV clinical trials are publicly registered under new indications, indicating the drug's established clinical profile remains consistent.

Ongoing Clinical Research

  • New indications: No recent trials target novel psychiatric or neurological conditions.
  • Post-marketing studies: Some research investigates long-term safety and efficacy; none are focused on expanded labeling.
  • Repurposing efforts: Limited studies explore off-label uses, mainly in psychiatric comorbidities.

Overall, the clinical landscape suggests stability without major new development efforts for Sertraline Hydrochloride.

What is the current market landscape?

Market Size and Revenue

The global antidepressant market was valued at approximately $15 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 2.5% through 2030, driven by increasing mental health awareness and diagnosis rates [1].

Sertraline's Market Share:

  • Dominates the SSRI market segment with approximately 25%-30% share.
  • Estimated global sales close to $3.8 billion annually.

Regional Distribution

  • United States: Largest market, accounting for over 50% of sales.
  • Europe: Significant market, with generic versions available.
  • Asia-Pacific: Growing demand, influenced by mental health awareness and improved healthcare access.

Competitive Landscape

Main competitors include fluoxetine, paroxetine, and escitalopram, with generics accounting for over 70% of sales. Patents expired in late 2000s, leading to a dominant generic market.

Regulatory Environment

  • Patent expirations: Multiple generics approved since 2008.
  • Pricing pressures: Reduced branded prices; increased reliance on generics.
  • Off-label usage: Some off-label applications face less regulatory scrutiny, sustaining demand.

What are future market projections?

Forecasted Market Trends

  • Growth drivers: Rising mental health disorder prevalence, greater acceptance of psychiatric medication, aging populations.
  • Market size: Expected to reach $17.5 billion by 2030, with SSRI segment maintaining leadership.
  • Generics influence: Continued dominance; branded sales declining unless new formulations or indications are developed.

Innovation and Development

Limited pipeline activity indicates low likelihood of new formulations or indications within the next five years, barring breakthroughs in mental health treatment strategies.

Impact of Digital Health

The integration of digital therapeutics could influence antidepressant demand, possibly supplementing medication use rather than replacing it.

Key Takeaways

  • Sertraline Hydrochloride remains a cornerstone in depression and anxiety management with no ongoing large-scale clinical trials for new indications.
  • The global market, heavily reliant on generics, sustains annual sales near $4 billion.
  • Market growth is modest, driven by demographic trends and mental health awareness, with expanding use in emerging markets.
  • Innovation in treatment approaches and digital health may influence future demand and competition dynamics.

FAQs

1. Are there any new formulations of Sertraline being developed?
No significant development in new formulations reported; existing products remain unchanged.

2. Could Sertraline gain approval for new psychiatric indications?
Current clinical trial activity does not suggest imminent expansion into new indications.

3. How does patent expiration impact the market?
Patent expirations have led to widespread generic availability, reducing prices and profit margins for branded versions.

4. What are the primary risks to Sertraline's market?
Emerging digital therapies, off-label substitution by generics, and competitive pharmaceutical advances.

5. Will market growth continue?
Yes, but at a slow pace, largely driven by demographic factors rather than pharmaceutical innovation.


References

[1] Grand View Research. (2023). Antidepressant drugs market size, share & trends analysis report.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.